A Universal Prophylactic Vaccine For Hepatitis C Virus
Funder
National Health and Medical Research Council
Funding Amount
$643,337.00
Summary
Hepatitis C Virus (HCV) infects 200 million people world wide. An effective vaccine to prevent HCV is urgently needed but must afford protection against the 7 diverse genotypes. In this project grant we aim to further define the quality of the immune response that is generated by a novel HCV vaccine candidate that generates pan-genotypic immunity, its unique structural features, and methods of manufacturing so that it can be tested in a future phase I human clinical trial.
Prophylactic Vaccine Development For The Elimination Of Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$936,752.00
Summary
A vaccine that prevents Hepatitis C is urgently needed to prevent infection and assist with global HCV elimination targets. This project grant will advance world-leading HCV vaccine candidates that generate both humoral and cellular immunity for clinical development.
Roles Of The Hepatitis C Virus Glycoprotein E2 Variable Regions In Virus Entry, Immunogenicity And Immune Evasion.
Funder
National Health and Medical Research Council
Funding Amount
$682,820.00
Summary
Hepatitis C Virus infects 200 million people world-wide with over 200,000 Australians infected with the disease. This project will examine how the surface proteins of HCV change their shape to evade antibody responses and how this effects the outcome of infection. We will further characterize a vaccine that elicits protective immunity to HCV to identify the optimal formulation for clinical trials.
CLINICAL RESEARCH TO UNDERSTAND ACQUIRED IMMUNITY TO DENGUE VIRUSES
Funder
National Health and Medical Research Council
Funding Amount
$841,953.00
Summary
Dengue, the commonest arboviral disease of humans, is caused by any of the four serotypes of dengue virus (DENV-1-4). This clinical research project will explore how acquired immunity to dengue viruses is expressed. The results will help dengue vaccine developers make better vaccines for use in Australian travellers and in dengue endemic countries in SE Asia.
Chimeric Insect-specific Flaviviruses: A New Generation Of Diagnostics And Vaccines Against Mosquito-borne Viral Disease
Funder
National Health and Medical Research Council
Funding Amount
$549,937.00
Summary
Dengue, Zika and West Nile are mosquito-borne viruses that cause disease outbreaks world-wide. We will develop safe, cheap and authentic diagnostics and vaccines against these diseases based on novel viruses that only infect mosquitoes. This is a timely paradigm shift for vaccine and diagnostic development. This innovative strategy will have high impact in the field of vector-borne viral diseases and provide a blueprint to develop safe diagnostics and vaccines for other mosquito-borne diseases.
Viral Targeting Of STAT Proteins: Roles In Disease
Funder
National Health and Medical Research Council
Funding Amount
$536,985.00
Summary
The capacity of viruses to evade the host immune response is critical to the development of disease. We recently showed that interaction of specific viral proteins with host immune proteins called STATs is vital to lethal disease caused by lyssaviruses. In this project, we aim to define in detail the functions of these interactions in viral modification of host biology and evasion of the immune response, and to use this information to develop new vaccines against highly pathogenic human viruses.
The Role Of Capsid Protein Nucleolar Localisation In Chikungunya Virus: Implications For Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$520,520.00
Summary
Chikungunya virus (CHIKV) is a globally widespread mosquito-borne alphavirus capable of causing considerable human morbidity and mortality. With no CHIKV vaccine or antiviral available this proposal aims to develop a live attenuated CHIKV vaccine, rationally designed by investigating the host cell nucleolar trafficking of CHIKV capsid protein. This vaccine has the potential to provide cross-protection against additional arthritogenic alphaviruses endemic to Australia such as Ross River virus.
Characterisation Of Rotavirus Vaccine Escape - Potential For Significant Impact On Vaccination Program
Funder
National Health and Medical Research Council
Funding Amount
$531,689.00
Summary
The introduction of rotavirus vaccines have had enormous impact on improving the health of children worldwide. However, the emergence of vaccine escape strains has the potential to significantly reduce the vaccine effectiveness. This study proposes to characterise strains able to escape vaccine protection.
Viruses are considered neither live nor dead, and it is understood that biological process within a virus must occur after it infects a cell. Our work reveals a previous unknown step in HIV known as pre-entry priming. These discoveries challenge our current dogma of how viruses function, and imply this pre-entry priming process is a built in mechanism for HIV to protect itself. This proposal will redefine our understanding of HIV and explore novel HIV vaccine design through these discoveries.